🇺🇸 Aracytine in United States
899 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 28 March 2025 – 28 March 2026
- Total reports: 899
Most-reported reactions
- Febrile Bone Marrow Aplasia — 126 reports (14.02%)
- Bone Marrow Failure — 112 reports (12.46%)
- Thrombocytopenia — 111 reports (12.35%)
- Pyrexia — 100 reports (11.12%)
- Acute Kidney Injury — 89 reports (9.9%)
- Off Label Use — 83 reports (9.23%)
- Diarrhoea — 79 reports (8.79%)
- Acute Myeloid Leukaemia — 68 reports (7.56%)
- Venoocclusive Liver Disease — 68 reports (7.56%)
- Septic Shock — 63 reports (7.01%)
Other Other approved in United States
Frequently asked questions
Is Aracytine approved in United States?
Aracytine does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Aracytine in United States?
The Lymphoma Academic Research Organisation is the originator. The local marketing authorisation holder may differ — check the official source linked above.